Sandbox: Difference between revisions

Revision as of 18:24, 2 October 2012

Do Not Delete

Class I
a. LDL-C should be <100 mg/dL. (Level of Evidence: A)
b. If baseline LDL-C is ≥100 mg/dL, initiate LDL-lowering drug therapy. (Level of Evidence: A)
c. If on-treatment LDL-C is ≥100 mg/dL, intensify LDL-lowering drug therapy (may require LDL-lowering drug combination). (Level of Evidence: A)
d. If triglycerides are 200 to 499 mg/dL, non-HDL-C should be <130 mg/dL. (Level of Evidence:B)
e. Therapeutic options to reduce non HDL - C are more intense LDL - C lowering therapy. (Level of Evidence:B)
f. If triglycerides are ≥500 mg/dL, therapeutic options to prevent pancreatitis are fibrate or niacin before LDL-lowering therapy; and treat LDL-C to goal after triglyceride-lowering therapy. Achieve non-HDL-C <130 mg/dL if possible. (Level of Evidence:C)

Class IIa
a. Reduction of LDL-C to <70 mg/dL is reasonable. (Level of Evidence:A)
b. If baseline LDL-C is 70 to 100 mg/dL, it is reasonable to treat to LDL-C <70 mg/dL. (Level of Evidence:B)
c. If triglycerides are 200 to 499 mg/dL, reduction of non-HDL-C to <100 mg/dL is reasonable. (Level of Evidence:B)
d. Therapeutic options to reduce non HDL - C are Niacin (after LDL-C loweing therapy). (Level of Evidence:B)
e. Therapeutic options to reduce non HDL - C are Fibrate therapy (after LDL-C loweing therapy). (Level of Evidence:B)

Class I
a. LDL-C should be <100 mg/dL. (Level of Evidence: A)
b. If baseline LDL-C is ≥100 mg/dL, initiate LDL-lowering drug therapy. (Level of Evidence: A)
c. If on-treatment LDL-C is ≥100 mg/dL, intensify LDL-lowering drug therapy (may require LDL-lowering drug combination). (Level of Evidence: A)
d. If triglycerides are 200 to 499 mg/dL, non-HDL-C should be <130 mg/dL. (Level of Evidence:B)
e. Therapeutic options to reduce non HDL - C are more intense LDL - C lowering therapy. (Level of Evidence:B)
f. If triglycerides are ≥500 mg/dL, therapeutic options to prevent pancreatitis are fibrate or niacin before LDL-lowering therapy; and treat LDL-C to goal after triglyceride-lowering therapy. Achieve non-HDL-C <130 mg/dL if possible. (Level of Evidence:C)

Class IIa
a. Reduction of LDL-C to <70 mg/dL is reasonable. (Level of Evidence:A)
b. If baseline LDL-C is 70 to 100 mg/dL, it is reasonable to treat to LDL-C <70 mg/dL. (Level of Evidence:B)
c. If triglycerides are 200 to 499 mg/dL, reduction of non-HDL-C to <100 mg/dL is reasonable. (Level of Evidence:B)
d. Therapeutic options to reduce non HDL - C are Niacin (after LDL-C loweing therapy). (Level of Evidence:B)
e. Therapeutic options to reduce non HDL - C are Fibrate therapy (after LDL-C loweing therapy). (Level of Evidence:B)

Class III (No Benefit)
1. Genetic testing is not indicated in relatives when the index patient does not have a definitive pathogenic mutation. (Level of Evidence: B)
2. Ongoing clinical screening is not indicated in genotype-negative relatives in families with HOCM. (Level of Evidence: B)

@@ Line 69: / Line 69: @@
 |-
 |bgcolor="Yellow" |'''e.''' Therapeutic options to reduce non HDL - C are [[Fibrate]] therapy (after LDL-C loweing therapy). ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
+|}
+----
+{|class="wikitable"
+|-
+|colspan="1" style="text-align:center; background:Red"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit)
+|-
+|'''1.''' Genetic testing is not indicated in relatives when the index patient does not have a definitive pathogenic mutation. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])
+|-
+|'''2.''' Ongoing clinical screening is not indicated in genotype-negative relatives in families with [[HOCM]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])
 |}